Notícias e Atividades da Telomir Pharmaceuticals

Telomir Pharmaceuticals é uma empresa listada sob o símbolo TELO (US).

Veja o organograma con seus 5 executivos principais

Biografias mais buscadas da Telomir Pharmaceuticals

• Erez Aminov, Chairman of the Board and Chief Executive Officer
• Matthew Whalen, Director
• Ned MacPherson, Director

Recentes movimentos de executivos em Telomir Pharmaceuticals

• Alan Weichselbaum, Chief Financial Officer, deixou a Companhia  (Notícia publicada em 9 de junho de 2026).
• Andriy Mushak, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 9 de junho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Telomir Pharmaceuticals.

Telomir Pharmaceuticals possui 1.918 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Samsung Biologics has announced the acquisition of PolyPeptide Group  (publicado em 22 de julho de 2026).
• Ipsen adquiriu Memo Therapeutics (publicado em 22 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• David Ricks - President, Chief Executive Officer and Chairman of the Board da Eli Lilly
• Richard Saynor - Chief Executive Officer da Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Telomir Pharmaceuticals

• Press Releases - Telomir Pharmaceuticals, Inc. (TELO)
• Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - Telomir Pharmaceuticals, Inc.
• Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance - T
• News Release - Telomir Pharmaceuticals, Inc. (TELO)
• Press Releases - Telomir Pharmaceuticals, Inc. (TELO)
• News Release - Telomir Pharmaceuticals, Inc. (TELO)
• News Release - Telomir Pharmaceuticals, Inc. (TELO)
• News Release - Telomir Pharmaceuticals, Inc. (TELO)
• News Release - Telomir Pharmaceuticals, Inc. (TELO)
• Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Telomir Pharmaceuticals, Inc. (TELO)
• View more press releases Close

Redes sociais sobre Telomir Pharmaceuticals

• Telomir Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Telomir Pharmaceuticals na LinkedIn, X (Twitter) e YouTube